Resolution of the Joint Meeting of the Expert Council "Hypoparathyroidism in the Era of Complex Problems and Breakthrough Technologies"

On March 25, 2026, a meeting of the Expert Council entitled "Hypoparathyroidism in the Era of Complex Challenges and Breakthrough Technologies" was held in Moscow at the Endocrinology Research Centre. The meeting focused on the epidemiology of chronic hypoparathyroidism (hypoPT) in Russia, the specifics of patient management with this pathology in other countries, and the similarities and differences between international and Russian clinical guidelines.

The meeting discussed advances in improving diagnostics and personalized treatment for patients with hypoPT in Russia, as well as the need to implement best practices in practical healthcare as part of the 2027 clinical guidelines revision.

The importance of including chronic hypoPT in the official list of rare (orphan) diseases was highlighted, as was the need to continue studying the characteristics of the disease and its complications, diagnosis, monitoring, and prevention of hypoPT, including in the long term. The meeting also highlighted the relevance of an interdisciplinary professional alliance to achieve optimal treatment outcomes and improve the quality of life of patients with chronic hypoPT. The experts highlighted the need to implement innovative, effective treatment methods, including hormone replacement therapy for hypoPT. The Council discussed the efficacy and safety of the new therapeutic technology, TransCon parathyroid hormone. Invited expert Dilek Gogas Yavuz, MD, Professor at the Marmara University School of Medicine, Department of Endocrinology and Metabolism, Department of Internal Medicine (Istanbul, Turkey), shared her experience with the drug and the results of international clinical trials. This resolution is a summary of the issues discussed in the Council members’ presentations and during the professional discussions.

1. Kovaleva EV, Salimkhanov RK, Elfimova AR, Eremkina AK, Pershina-Miliutina AP, et al. Complications of chronic hypoparathyroidism according to analysis database Russian Registry. Clinical and experimental thyroidology. 2024;20(1):30-40. (In Russ.) doi: https://doi.org/10.14341/ket12792

2. Salimkhanov RKh, Kovaleva EV, Elfimova AR, Eremkina AK, Pershina-Miliutina AP, et al. Clinical profile of patients with chronic hypoparathyroidism according to the All-Russian registry. Clinical and experimental thyroidology. 2024;20(2):27-37. (In Russ.) doi: https://doi.org/10.14341/ket12802

3. Kovaleva EV, Eremkina AK, Elfimova AR, Krupinova JA, Bibik EE, et al. The Russian Registry of Chronic Hypoparathyroidism. Front. Endocrinol. 13:800119. doi: https://doi.org/10.3389/fendo.2022.800119

4. Hronicheskij gipoparatireoz: prediktory razvitiya oslozhnenij zabolevaniya i personalizaciya vedeniya pacientov. Kovaleva EV. — Diss. na soiskanie uch. st. k.m.n., 2022 g. (In Russ.)

5. Kovaleva EV, Eremkina AK, Ajnetdinova R, Miliutina P, Mokrysheva NG. The Russian registry of chronic hypoparathyroidism and clinical decision support system integration. Problems of Endocrinology. 2021;67(4):8-12. (In Russ.) doi: https://doi.org/10.14341/probl12796

6. Sposob individualizirovannogo podbora doz lekarstvennyh preparatov dlya lecheniya pacientov s hronicheskim gipoparatireozom. Mokrysheva Natal’ya Georgievna, Eremkina Anna Konstantinovna, Kovaleva Elena Vladimirovna, Elfimova Alina Rinatovna, Pershina-Milyutina Anastasiya Pavlovna. Patent na izobretenie №2861630, 6 maya 2026 g. (In Russ.)

7. Перечень редких (орфанных) заболеваний, Минздрав России, от 14 апреля 2026 года, https://minzdrav.gov.ru/documents/9863-perechen-redkih-orfannyh-zabolevaniy.

8. Bollerslev J, Rejnmark L, Marcocci C, Shoback DM, Sitges-Serra A, et al; European Society of Endocrinology. European Society of Endocrinology Clinical Guideline: Treatment of chronic hypoparathyroidism in adults. Eur J Endocrinol. 2015;173(2):G1-20. doi: https://doi.org/10.1530/EJE-15-0628

9. Bollerslev J, Buch O, Cardoso LM, Gittoes N, Houillier P, et al. Revised European Society of Endocrinology Clinical Practice Guideline: Treatment of Chronic Hypoparathyroidism in Adults. Eur J Endocrinol. 202;193(5):G49-G78. doi: https://doi.org/10.1093/ejendo/lvaf222

10. Misiorowski W, Kos-Kudła B, Hubalewska-Dydejczyk A, Ruchała M, Zgliczyński W, et al. Treatment of hypoparathyroidism (HypoPT): Position Statement of the Expert Group for Polish Society of Endocrinology - update 2026. Endokrynol Pol. 2026;77(1):1-4. doi: https://doi.org/10.5603/ep.110591

11. Guidelines on the therapeutic management of post-surgical hypoparathyroidism in adults. Association of Endocrinologists (AME), Italian Society of Endocrinology (SIE), Italian Society of Orthopedics and Traumatology (SIOT), Italian Society of Osteoporosis, Mineral Metabolism and Skeletal Diseases (SIOMMMS), Italian Society of Endocrine Surgery (SIUEC), Istituto Superiore di Sanità, 2025

12. Guidelines for the Diagnosis and Treatment of Osteoporosis and Metabolic Bone Diseases. Turkish Society of Endocrinology and Metabolism, 2025

13. Klinicheskie rekomendacii po gipoparatireozu u vzroslyh. Ministerstvo zdravoohraneniya Rossijskoj Federacii, 2025 g.

14. Kovaleva EV, Eremkina AK, Mokrysheva NG. Daily calcium profile in diagnosis of hypo- and hypercalcemia in patients with chronic hypoparathyroidism. clinical case series. Obesity and metabolism. 2021;18(2):175-179. (In Russ.) doi: https://doi.org/10.14341/omet12729

15. Kovaleva EV, Eremkina AK, Mokrysheva NG. Chronic hypoparathyroidism: clinical manifestations, complications and impact on the quality of life. FOCUS. Endocrinology. 2023;4(1):78-83. (In Russ.) doi: https://doi.org/10.15829/2713-0177-2023-27

16. Arlt W, Fremerey C, Callies F, et al. Well-being, mood and calcium homeostasis in patients with hypoparathyroidism receiving standard treatment with calcium and vitamin D. Eur J Endocrinol. Published online February 1, 2002:215-222. doi: https://doi.org/10.1530/eje.0.1460215

17. Sikjaer T, Moser E, Rolighed L, et al. Concurrent Hypoparathyroidism Is Associated With Impaired Physical Function and Quality of Life in Hypothyroidism. Journal of Bone and Mineral Research. 2016;31(7):1440-1448. doi: 10.1002/jbmr.2812

18. Underbjerg L, Sikjaer T, Rejnmark L. Health‐related quality of life in patients with nonsurgical hypoparathyroidism and pseudohypoparathyroidism. Clin Endocrinol (Oxf ). 2018;88(6):838-847. doi: https://doi.org/10.1111/cen.13593

19. Siggelkow H, Clarke BL, Germak J, et al. Burden of illness in not adequately controlled chronic hypoparathyroidism: Findings from a 13‐country patient and caregiver survey. Clin Endocrinol (Oxf ). 2020;92(2):159-168. doi: https://doi.org/10.1111/cen.14128

20. Winer KK, et al. Long-term treatment of hypoparathyroidism: a randomized controlled study comparing parathyroid hormone-(1-34) versus calcitriol and calcium. J. Clin. Endocrinol. Metab. United States. 2003;88(9):4214–4220. doi: https://doi.org/10.1210/jc.2002-021736

21. Marcucci G, et al. Chronic hypoparathyroidism and treatment with teriparatide. Endocrine. 2021;72(1):249-259. doi: https://doi.org/10.1007/s12020-020-02577-x

22. Winer KK, et al. Effects of once versus twice-daily parathyroid hormone 1-34 therapy in children with hypoparathyroidism. J. Clin. Endocrinol. Metab. 2008;93(9): 3389–3395. doi: https://doi.org/10.1210/jc.2007-2552

23. Winer KK, et al. Long-Term Parathyroid Hormone 1-34 Replacement Therapy in Children with Hypoparathyroidism. J. Pediatr. Elsevier Inc. 2018;203(391-399):e1. doi: https://doi.org/10.1016/j.jpeds.2018.08.010

24. Karpf DB, Pihl S, Mourya S, Mortensen E, Kovoor E, Markova D, Leff JA. A Randomized Double-Blind Placebo-Controlled First-In-Human Phase 1 Trial of TransCon PTH in Healthy Adults. J Bone Miner Res. 2020;35(8):1430-1440. doi: 10 doi: https://doi.org/.1002/jbmr.4016

25. Khan AA, Rejnmark L, Rubin M, Schwarz P, Vokes T, Clarke B, et al. PaTH Forward: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of TransCon PTH in Adult Hypoparathyroidism. J Clin Endocrinol Metab. 2022;107(1):e372-e385. doi: https://doi.org/10.1210/clinem/dgab577

26. Khan AA, Rubin MR, Schwarz P, Vokes T, Shoback DM, Gagnon C, et al. Efficacy and Safety of Parathyroid Hormone Replacement With TransCon PTH in Hypoparathyroidism: 26-Week Results From the Phase 3 PaTHway Trial. J Bone Miner Res. 2023;38(1):14-25. doi: https://doi.org/10.1002/jbmr.4726

27. Bart L Clarke, Aliya A Khan, Mishaela R Rubin, Peter Schwarz, Tamara Vokes, et al., Efficacy and Safety of TransCon PTH in Adults With Hypoparathyroidism: 52-Week Results From the Phase 3 PaTHway Trial. The Journal of Clinical Endocrinology & Metabolism. 2025;110(4):951–960. doi: https://doi.org/10.1210/clinem/dgae693